Skip to main content

Prognostic significance of standardized uptake value and metabolic tumour volume on 18F-FDG PET/CT in oropharyngeal squamous cell carcinoma

European Journal of Nuclear Medicine and Molecular Imaging volume 42, pages 1353–1361 (2015)Cite this article

Abstract

Purpose

Standardized uptake value (SUV) and metabolic tumour volume (MTV) measured by 18F-FDG PET/CT are emerging prognostic biomarkers in human solid cancers. However, their prognostic significance in oropharyngeal squamous cell carcinoma (OPSCC) has been investigated in only a few studies and with small cohorts. In the present study we evaluated the ability of SUV, MTV, and total lesion glycolysis (TLG) measured on pretreatment 18F-FDG PET/CT to predict recurrence and survival outcomes in OPSCC.

Methods

The study included 221 patients with OPSCC who underwent pretreatment 18F-FDG PET/CT imaging and received definitive treatment at our tertiary referral centre. The PET imaging parameters SUVmax, SUVpeak, MTV and TLG were measured in primary tumours with focal 18F-FDG uptake. Clinical and imaging variables significantly associated with overall survival (OS) and disease-free survival (DFS) were identified by univariate and multivariate analyses using the Cox proportional hazards model.

Results

Overall 5-year OS and DFS rates were 72.0 % and 79.5 %, respectively, during a median follow-up of 61 months (range 18 – 122 months). The cut-off values of tumour SUVmax, SUVpeak, MTV and TLG for prediction of DFS were 7.55, 6.80, 11.06 mL and 78.56 g, respectively. Univariate analyses showed that age >60 years, advanced tumour stage, and high tumour SUVmax, SUVpeak, MTV and TLG were significantly associated with decreased OS and DFS (P < 0.05 each). Age, tumour SUVmax and MTV remained independent variables for OS and DFS (P < 0.05 each) in the multivariate analyses.

Conclusion

SUVmax and MTV measured on pretreatment 18F-FDG PET/CT may be useful in predicting the clinical outcomes in OPSCC patients.

Condensed abstract

This study investigated the clinical prognostic value of imaging parameters from pretreatment 18F-FDG PET/CT in 221 patients who underwent definitive treatment for oropharyngeal squamous cell carcinoma. High maximum standardized uptake value and metabolic tumour volume were independently associated with decreased disease-free and overall survival outcomes.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Fig. 1
Fig. 2

References

  1. Sturgis EM, Cinciripini PM. Trends in head and neck cancer incidence in relation to smoking prevalence: an emerging epidemic of human papillomavirus-associated cancers? Cancer. 2007;110(7):1429–35.

    PubMed  Article  Google Scholar 

  2. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64(1):9–29.

    PubMed  Article  Google Scholar 

  3. Pai SI, Westra WH. Molecular pathology of head and neck cancer: implications for diagnosis, prognosis, and treatment. Annu Rev Pathol. 2009;4:49–70.

    CAS  PubMed Central  PubMed  Article  Google Scholar 

  4. Setton J, Caria N, Romanyshyn J, Koutcher L, Wolden SL, Zelefsky MJ, et al. Intensity-modulated radiotherapy in the treatment of oropharyngeal cancer: an update of the Memorial Sloan-Kettering Cancer Center experience. Int J Radiat Oncol Biol Phys. 2012;82(1):291–8.

    PubMed  Article  Google Scholar 

  5. Huang K, Xia P, Chuang C, Weinberg V, Glastonbury CM, Eisele DW, et al. Intensity-modulated chemoradiation for treatment of stage III and IV oropharyngeal carcinoma: the University of California–San Francisco experience. Cancer. 2008;113(3):497–507.

    PubMed  Article  Google Scholar 

  6. Rischin D. Oropharyngeal cancer, human papilloma virus, and clinical trials. J Clin Oncol. 2010;28(1):1–3.

    CAS  PubMed  Article  Google Scholar 

  7. Patel SG, Lydiatt WM. Staging of head and neck cancers: is it time to change the balance between the ideal and the practical? J Surg Oncol. 2008;97(8):653–7.

    PubMed  Article  Google Scholar 

  8. Takes RP, Rinaldo A, Silver CE, Piccirillo JF, Haigentz Jr M, Suárez C, et al. Future of the TNM classification and staging system in head and neck cancer. Head Neck. 2010;32(12):1693–711.

    PubMed  Article  Google Scholar 

  9. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC cancer staging manual. 7th ed. New York, NY: Springer; 2010. p. 41–56.

    Google Scholar 

  10. Antoch G, Saoudi N, Kuehl H, Dahmen G, Mueller SP, Beyer T, et al. Accuracy of whole-body dual-modality fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomography and computed tomography (FDG-PET/CT) for tumor staging in solid tumors: comparison with CT and PET. J Clin Oncol. 2004;22(21):4357–68.

    PubMed  Article  Google Scholar 

  11. Lonneux M, Hamoir M, Reychler H, Haingon P, Duvillard C, Calais G, et al. Positron emission tomography with [18F]-fluorodeoxyglucose improves staging and patient management in patients with head and neck squamous cell carcinoma: a multicenter prospective study. J Clin Oncol. 2010;28(7):1190–5.

    CAS  PubMed  Article  Google Scholar 

  12. Schöder H, Fury M, Lee N, Kraus D. PET monitoring of therapy response in head and neck squamous cell carcinoma. J Nucl Med. 2009;50:74S–88S.

    PubMed  Article  Google Scholar 

  13. Moeller BJ, Rana V, Cannon BA, Williams MD, Sturgis EM, Ginsberg LE, et al. Prospective risk-adjusted [18F]fluorodeoxyglucose positron emission tomography and computed tomography assessment of radiation response in head and neck cancer. J Clin Oncol. 2009;27(15):2509–15.

    PubMed Central  PubMed  Article  Google Scholar 

  14. Allal AS, Slosman DO, Kebdani T, Allaoua M, Lehmann W, Dulguerov P. Prediction of outcome in head-and-neck cancer patients using the standardized uptake value of 2-[18F]fluoro-2-deoxy-D-glucose. Int J Radiat Oncol Biol Phys. 2004;59(5):1295–300.

    CAS  PubMed  Article  Google Scholar 

  15. Liao CT, Wang HM, Huang SF, Chen IH, Kang CJ, Lin CY, et al. PET and PET/CT of the neck lymph nodes improves risk prediction in patients with squamous cell carcinoma of the oral cavity. J Nucl Med. 2011;52(2):180–7.

    PubMed  Article  Google Scholar 

  16. Kim SY, Roh JL, Kim MR, Kim JS, Choi SH, Nam SY, et al. Use of 18F-FDG PET for primary treatment strategy in patients with squamous cell carcinoma of the oropharynx. J Nucl Med. 2007;48(5):752–7.

    PubMed  Article  Google Scholar 

  17. Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50 Suppl 1:122S–50S.

    CAS  PubMed Central  PubMed  Article  Google Scholar 

  18. Chung MK, Jeong HS, Park SG, Jang JY, Son YI, Choi JY, et al. Metabolic tumor volume of [18F]-fluorodeoxyglucose positron emission tomography/computed tomography predicts short-term outcome to radiotherapy with or without chemotherapy in pharyngeal cancer. Clin Cancer Res. 2009;15(18):5861–8.

    CAS  PubMed  Article  Google Scholar 

  19. Chen HH, Chiu NT, Su WC, Guo HR, Lee BF. Prognostic value of whole-body total lesion glycolysis at pretreatment FDG PET/CT in non-small cell lung cancer. Radiology. 2012;264(2):559–66.

    PubMed  Article  Google Scholar 

  20. Dibble EH, Alvarez AC, Truong MT, Mercier G, Cook EF, Subramaniam RM. 18F-FDG metabolic tumor volume and total glycolytic activity of oral cavity and oropharyngeal squamous cell cancer: adding value to clinical staging. J Nucl Med. 2012;53(5):709–15.

    CAS  PubMed  Article  Google Scholar 

  21. Park GC, Kim JS, Roh JL, Choi SH, Nam SY, Kim SY. Prognostic value of metabolic tumor volume measured by 18F-FDG PET/CT in advanced-stage squamous cell carcinoma of the larynx and hypopharynx. Ann Oncol. 2013;24(1):208–14.

    CAS  PubMed  Article  Google Scholar 

  22. Romesser PB, Lim R, Spratt DE, Setton J, Riaz N, Lok B, et al. The relative prognostic utility of standardized uptake value, gross tumor volume, and metabolic tumor volume in oropharyngeal cancer patients treated with platinum based concurrent chemoradiation with a pre-treatment [18F]fluorodeoxyglucose positron emission tomography scan. Oral Oncol. 2014;50(9):802–8.

    CAS  PubMed  Article  Google Scholar 

  23. Kikuchi M, Koyasu S, Shinohara S, Usami Y, Imai Y, Hino M, et al. Prognostic value of pretreatment 18F-fluorodeoxyglucose positron emission tomography/CT volume-based parameters in patients with oropharyngeal squamous cell carcinoma with known p16 and p53 status. Head Neck. 2014. doi:10.1002/hed.23784.

    Google Scholar 

  24. Lasnon C, Desmonts C, Quak E, Gervais R, Do P, Dubos-Arvis C, et al. Harmonizing SUVs in multicentre trials using different generation PET systems: prospective validation in non-small cell lung cancer patients. Eur J Nucl Med Mol Imaging. 2013;40(7):985–96.

    CAS  PubMed Central  PubMed  Article  Google Scholar 

  25. Boellaard R, O’Doherty MJ, Weber WA, Mottaghy FM, Lonsdale MN, Stroobants SG, et al. FDG PET and PET/CT: EANM procedure guidelines for tumor PET imaging: version 1.0. Eur J Nucl Med Mol Imaging. 2010;37(1):181–200.

    PubMed Central  PubMed  Article  Google Scholar 

  26. Kelly M. EQ-PET: Achieving NEMA-referenced SUV across technologies. Siemens Medical Solutions. http://www.healthcare.siemens.com/siemens_hwem-hwem_ssxa_websites-context-root/wcm/idc/groups/public/@global/@imaging/@molecular/documents/download/mdaz/nzy5/~edisp/eqpet_wp.final-01662575.pdf.

  27. Oh JS, Oh M, Chung SJ, Kim JS. Cerebellum-specific 18F-FDG PET analysis for the detection of subregional glucose metabolism changes in spinocerebellar ataxia. Neuroreport. 2014;25(15):1198–202.

    CAS  PubMed  Article  Google Scholar 

  28. Williams BA, Mandrekar JN, Mandrekar SJ, Cha SS, Furth AF. Finding optimal cutpoints for continuous covariates with binary and time-to-event outcomes. Rochester, MN: Department of Health Sciences Research Mayo Clinic; 2006.

    Google Scholar 

  29. Halfpenny W, Hain SF, Biassoni L, Maisey MN, Sherman JA, McGurk M. FDG-PET. A possible prognostic factor in head and neck cancer. Br J Cancer. 2002;86(4):512–6.

    CAS  PubMed Central  PubMed  Article  Google Scholar 

  30. Wong RJ, Lin DT, Schöder H, Patel SG, Gonen M, Wolden S, et al. Diagnostic and prognostic value of [18F]-fluorodeoxyglucose positron emission tomography for recurrent head and neck squamous cell carcinoma. J Clin Oncol. 2002;20(20):4199–208.

    CAS  PubMed  Article  Google Scholar 

  31. Lin SC, Liao CY, Kao CH, Yen KY, Yang SN, Wang YC, et al. Pretreatment maximal standardized uptake value of the primary tumor predicts outcome to radiotherapy in patients with pharyngeal cancer. J Radiat Res. 2012;53(3):462–8.

    PubMed  Article  Google Scholar 

  32. Joo YH, Yoo IR, Cho KJ, Park JO, Nam IC, Kim MS. Preoperative 18F-FDG PET/CT and high-risk HPV in patients with oropharyngeal squamous cell carcinoma. Head Neck. 2014;36(3):323–7.

    PubMed  Article  Google Scholar 

  33. Lim R, Eaton A, Lee NY, Setton J, Ohri N, Rao S, et al. 18F-FDG PET/CT metabolic tumor volume and total lesion glycolysis predict outcome in oropharyngeal squamous cell carcinoma. J Nucl Med. 2012;53(10):1506–13.

    CAS  PubMed  Article  Google Scholar 

  34. Paidpally V, Chirindel A, Lam S, Agrawal N, Quon H, Subramaniam RM. FDG-PET/CT imaging biomarkers in head and neck squamous cell carcinoma. Imaging Med. 2012;4(6):633–47.

    CAS  PubMed Central  PubMed  Article  Google Scholar 

  35. Chen SW, Hsieh TC, Yen KY, Liang JA, Kao CH. Pretreatment (18)F-FDG PET/CT in whole-body total lesion glycolysis to predict survival in patients with pharyngeal cancer treated with definitive radiotherapy. Clin Nucl Med. 2014;39(5):e296–300.

    PubMed  Article  Google Scholar 

  36. Moon SH, Choi JY, Lee HJ, Son YI, Baek CH, Ahn YC, et al. Prognostic value of 18F-FDG PET/CT in patients with squamous cell carcinoma of the tonsil: comparison of volume-based metabolic parameters. Head Neck. 2013;35(1):15–22.

    PubMed  Article  Google Scholar 

Download references

Compliance with ethical standards

ᅟ

Conflicts of interest

None.

Funding

This study was supported by a grant (no. 2014–0306) from the Asan Institute for Life Science and a grant (HI14C23050000) from the Korean Health Technology R&D Project, Ministry of Health & Welfare, Seoul, Republic of Korea, Seoul, Korea (J.-L. Roh).

Statement of human rights

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee and with the principles of the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. For this type of retrospective study, formal consent is not required.

Statement on the welfare of animals

This article does not describe any studies with animals performed by any of the authors.

Informed consent

For this type of retrospective study, informed consent from each patient was waived.

Author information

Author notes

    Affiliations

    1. Department of Otolaryngology, Asan Medical Centre, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul, 138-736, Republic of Korea

      Ji Won Kim, Jong-Lyel Roh, Seung-Ho Choi, Soon Yuhl Nam & Sang Yoon Kim

    2. Department of Nuclear Medicine, Asan Medical Centre, University of Ulsan College of Medicine, Seoul, Republic of Korea

      Jungsu S. Oh & Jae Seung Kim

    3. Korea Institute of Science and Technology, Biomedical Research Institute, Seoul, Republic of Korea

      Sang Yoon Kim

    Authors
    1. Ji Won Kim
      View author publications

      You can also search for this author in PubMed Google Scholar

    2. Jungsu S. Oh
      View author publications

      You can also search for this author in PubMed Google Scholar

    3. Jong-Lyel Roh
      View author publications

      You can also search for this author in PubMed Google Scholar

    4. Jae Seung Kim
      View author publications

      You can also search for this author in PubMed Google Scholar

    5. Seung-Ho Choi
      View author publications

      You can also search for this author in PubMed Google Scholar

    6. Soon Yuhl Nam
      View author publications

      You can also search for this author in PubMed Google Scholar

    7. Sang Yoon Kim
      View author publications

      You can also search for this author in PubMed Google Scholar

    Corresponding author

    Correspondence to Jong-Lyel Roh.

    Additional information

    Ji Won Kim and Jungsu S. Oh contributed equally to this work.

    Rights and permissions

    Reprints and Permissions

    About this article

    Verify currency and authenticity via CrossMark

    Cite this article

    Kim, J.W., Oh, J.S., Roh, JL. et al. Prognostic significance of standardized uptake value and metabolic tumour volume on 18F-FDG PET/CT in oropharyngeal squamous cell carcinoma. Eur J Nucl Med Mol Imaging 42, 1353–1361 (2015). https://doi.org/10.1007/s00259-015-3051-4

    Download citation

    • Received:

    • Accepted:

    • Published:

    • Issue Date:

    • DOI: https://doi.org/10.1007/s00259-015-3051-4

    Keywords

    • Oropharyngeal squamous cell carcinoma
    • 18F-FDG PET/CT
    • Standardized uptake value
    • Metabolic tumour volume
    • Prognostic factor